Reflection paper on a tailored clinical approach in biosimilar development
The European Medicines Agency (EMA) is exploring an improved approach for biosimilar medicine development and evaluation, while upholding strict European Union (EU) safety standards. The is outlined in a draft reflection paper biosimilar development. Its aim is to reduce the amount of clinical data required for the development and approval of biosimilar medicines in the EU.
Human
Scientific guidelines